Gender and the renin-angiotensin-aldosterone system

Fundamental and Clinical Pharmacology

Volumn 24, Issue 6, 2010, Pages 687-698

  Komukai, Kimiaki ^a   Mochizuki, Seibu ^b   Yoshimura, Michihiro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MUSASHINO UNIVERSITY   (Japan)

Author keywords

Androgens; Angiotensin receptor; Natriuretic peptides; Oestrogen

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; ANGIOTENSINOGEN; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FLUTAMIDE; MEDROXYPROGESTERONE; PROGESTERONE; RENIN; SEX HORMONE; TESTOSTERONE;

BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CHRONIC KIDNEY DISEASE; GLOMERULUS FILTRATION RATE; HEART CONTRACTION; HEART FAILURE; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; JUXTAGLOMERULAR CELL; MENSTRUAL CYCLE; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; SEX DIFFERENCE;

CARDIOVASCULAR DISEASES; ESTROGENS; FEMALE; HUMANS; KIDNEY DISEASES; MALE; RENIN-ANGIOTENSIN SYSTEM; SEX FACTORS; TESTOSTERONE;

EID: 78349258986     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00854.x     Document Type: Review

References (110)

1. Kannel W.B., Hjortland M.C., McNamara P.M., Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann. Intern. Med. (1976) 85 447-452.
2. Wiinberg N., Høegholm A., Christensen H.R. et al. 24-h ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am. J. Hypertens. (1995) 10 978-986.
3. Hannedouche T., Chauveau P., Kalou F., Albouze G., Lacour B., Jungers P. Factors affecting progression in advanced chronic renal failure. Clin. Nephrol. (1993) 39 312-320.
4. Silbiger S.R., Neugarten J. The impact of gender on the progression of chronic renal disease. Am. J. Kidney Dis. (1995) 25 515-533.
5. Jungers P., Chauveau P., Descamps-Latscha B. et al. Age and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study. Nephrol. Dial. Transplant. (1996) 11 1542-1546.
6. Danser A.H., Derkx F.H., Schalekamp M.A., Hense H.W., Riegger G.A., Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J. Hypertens. (1998) 16 853-862.
7. Schunkert H., Danser A.H., Hense H.W., Derkx F.H., Kürzinger S., Riegger G.A. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation (1997) 95 39-45.
8. De Lignieres B., Basdevant A., Thomas G. et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J. Clin. Endocrinol. Metab. (1986) 62 536-541.
9. Hassager C., Riis B.J., Strøm V., Guyene T.T., Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation (1987) 76 753-758.
10. Harvey P.J., Morris B.L., Miller J.A., Floras J.S. Estradiol induces discordant angiotensin and blood pressure responses to orthostasis in healthy postmenopausal women. Hypertension (2005) 45 399-405.
11. Fischer M., Baessler A., Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc. Res. (2002) 53 672-677.
12. Clauser E., Gaillard I., Wei L., Corvol P. Regulation of angiotensinogen gene. Am. J. Hypertens. (1989) 2 403-410.
13. Feldmer M., Kaling M., Takahashi S., Mullins J.J., Ganten D. Glucocorticoid- and estrogen-responsive elements in the 5'-flanking region of the rat angiotensinogen gene. J. Hypertens. (1991) 9 1005-1012.
14. Ellison K.E., Ingelfinger J.R., Pivor M., Dzau V.J. Androgen regulation of rat renal angiotensinogen messenger RNA expression. J. Clin. Invest. (1989) 83 1941-1945.
15. Chen Y.F., Naftilan A.J., Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension (1992) 19 456-463.
16. Yanes L.L., Sartori-Valinotti J.C., Iliescu R. et al. Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats. Am. J. Physiol. Renal Physiol. (2009) 296 F771-F779.
17. Klett C., Ganten D., Hellmann W. et al. Regulation of hepatic angiotensinogen synthesis and secretion by steroid hormones. Endocrinology (1992) 130 3660-3668.
18. Seely E.W., Walsh B.W., Gerhard M.D., Williams G.H. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension (1999) 33 1190-1194.
19. Pendergrass K.D., Pirro N.T., Westwood B.M., Ferrario C.M., Brosnihan K.B., Chappell M.C. Sex differences in circulating and renal angiotensins of hypertensive mRen(2).Lewis but not normotensive Lewis rats. Am. J. Physiol. Heart Circ. Physiol. (2008) 295 H10-H20.
20. Baltatu O., Cayla C., Iliescu R., Andreev D., Bader M. Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats. Hypertension (2003) 41 830-833.
21. Pratt R.E., Dzau V.J., Ouellette A.J. Influence of androgen on translatable renin mRNA in the mouse submandibular gland. Hypertension (1984) 6 605-613.
22. Lloyd T., Weisz J. Direct inhibition of tyrosine hydroxylase activity by catechol estrogens. J. Biol. Chem. (1978) 253 4841-4843.
23. Landazuri P., Granobles C., Loango N. Gender differences in serum angiotensin-converting enzyme activity and blood pressure in children: an observational study. Arq. Bras. Cardiol. (2008) 91 352-357.
24. Zapater P., Novalbos J., Gallego-Sandín S., Hernández F.T., Abad-Santos F. Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers. J. Cardiovasc. Pharmacol. (2004) 43 737-744.
25. Miller J.A., Anacta L.A., Cattran D.C. Impact of gender on the renal response to angiotensin II. Kidney Int. (1999) 55 278-285.
26. Proudler A.J., Ahmed A.I., Crook D., Fogelman I., Rymer J.M., Stevenson J.C. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet (1995) 346 89-90.
27. Ichikawa J., Sumino H., Ichikawa S., Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am. J. Hypertens. (2006) 19 744-749.
28. Brosnihan K.B., Weddle D., Anthony M.S., Heise C., Li P., Ferrario C.M. Effects of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. J. Hypertens. (1997) 15 719-726.
29. Gallagher P.E., Li P., Lenhart J.R., Chappell M.C., Brosnihan K.B. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension (1999) 33 323-328.
30. Dean S.A., Tan J., O'Brien E.R., Leenen F.H. 17beta-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 288 R759-R766.
31. Freshour J.R., Chase S.E., Vikstrom K.L. Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice. Am. J. Physiol. Heart Circ. Physiol. (2002) 283 H1997-H2003.
32. Brosnihan K.B., Li P., Ganten D., Ferrario C.M. Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS. Am. J. Physiol. (1997) 273 R1908-R1915.
33. Xu X., Xiao J.C., Luo L.F. et al. Effects of ovariectomy and 17beta-estradiol treatment on the renin-angiotensin system, blood pressure, and endothelial ultrastructure. Int. J. Cardiol. (2008) 130 196-204.
34. Sullivan J.C., Semprun-Prieto L., Boesen E.I., Pollock D.M., Pollock J.S. Sex and sex hormones influence the development of albuminuria and renal macrophage infiltration in spontaneously hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2007) 293 R1573-R1579.
35. Wettschureck N., Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol. Rev. (2005) 85 1159-1204.
36. Owonikoko T.K., Fabucci M.E., Brown P.R. et al. In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET. J. Nucl. Med. (2004) 45 94-100.
37. Rogers J.L., Mitchell A.R., Maric C., Sandberg K., Myers A., Mulroney S.E. Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2007) 292 R794-R799.
38. Nickenig G., Bäumer A.T., Grohè C. et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation (1998) 97 2197-2201.
39. Macova M., Armando I., Zhou J. et al. Estrogen reduces aldosterone, upregulates adrenal angiotensin II AT2 receptors and normalizes adrenomedullary Fra-2 in ovariectomized rats. Neuroendocrinology (2008) 88 276-286.
40. Wu Z., Maric C., Roesch D.M., Zheng W., Verbalis J.G., Sandberg K. Estrogen regulates adrenal angiotensin AT1 receptors by modulating AT1 receptor translation. Endocrinology (2003) 144 3251-3261.
41. Krishnamurthi K., Verbalis J.G., Zheng W., Wu Z., Clerch L.B., Sandberg K. Estrogen regulates angiotensin AT1 receptor expression via cytosolic proteins that bind to the 5' leader sequence of the receptor mRNA. Endocrinology (1999) 140 5435-5438.
42. Song J., Kost C.K. Jr, Martin D.S. Androgens augment renal vascular responses to ANG II in New Zealand genetically hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2006) 290 R1608-R1615.
43. Silva-Antonialli M.M., Tostes R.C., Fernandes L. et al. A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats. Cardiovasc. Res. (2004) 62 587-593.
44. Nickenig G., Strehlow K., Wassmann S. et al. Differential effects of estrogen and progesterone on AT(1) receptor gene expression in vascular smooth muscle cells. Circulation (2000) 102 1828-1833.
45. Horiuchi M., Akishita M., Dzau V.J. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension (1999) 33 613-621.
46. Shanmugam S., Corvol P., Gasc J.M. Angiotensin II type 2 receptor mRNA expression in the developing cardiopulmonary system of the rat. Hypertension (1996) 28 91-97.
47. Koike G., Horiuchi M., Yamada T., Szpirer C., Jacob H.J., Dzau V.J. Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung. Biochem. Biophys. Res. Commun. (1994) 203 1842-1850.
48. Armando I., Jezova M., Juorio A.V. et al. Estrogen upregulates renal angiotensin II AT(2) receptors. Am. J. Physiol. Renal Physiol. (2002) 283 F934-F943.
49. Okumura M., Iwai M., Ide A., Mogi M., Ito M., Horiuchi M. Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression. Hypertension (2005) 46 577-583.
50. De P Rodrigues S.F., Dos Santos R.A., Silva-Antonialli M.M. et al. Differential effect of losartan in female and male spontaneously hypertensive rats. Life Sci. (2006) 78 2280-2285.
51. Xue B., Pamidimukkala J., Hay M. Sex differences in the development of angiotensin II-induced hypertension in conscious mice. Am. J. Physiol. Heart Circ. Physiol. (2005) 288 H2177-H2184.
52. Ebrahimian T., He Y., Schiffrin E.L., Touyz R.M. Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice. J. Hypertens. (2007) 25 1263-1271.
53. Sartori-Valinotti J.C., Iliescu R., Yanes L.L., Dorsett-Martin W., Reckelhoff J.F. Sex differences in the pressor response to angiotensin II when the endogenous renin-angiotensin system is blocked. Hypertension (2008) 51 1170-1176.
54. Dantas A.P., Franco Mdo C., Silva-Antonialli M.M. et al. Gender differences in superoxide generation in microvessels of hypertensive rats: role of NAD(P)H-oxidase. Cardiovasc. Res. (2004) 61 22-29.
55. Tsuda M., Iwai M., Li J.M. et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension (2005) 45 545-551.
56. Stewart J.A. Jr, Cashatt D.O., Borck A.C., Brown J.E., Carver W.E. 17beta-estradiol modulation of angiotensin II-stimulated response in cardiac fibroblasts. J. Mol. Cell. Cardiol. (2006) 41 97-107.
57. Wu M., Han M., Li J. et al. 17beta-estradiol inhibits angiotensin II-induced cardiac myofibroblast differentiation. Eur. J. Pharmacol. (2009) 616 155-159.
58. Funder J.W. Mineralocorticoid receptors: distribution and activation. Heart Fail. Rev. (2005) 10 15-22.
59. Roesch D.M., Tian Y., Zheng W., Shi M., Verbalis J.G., Sandberg K. Estradiol attenuates angiotensin-induced aldosterone secretion in ovariectomized rats. Endocrinology (2000) 141 4629-4636.
60. Szmuilowicz E.D., Adler G.K., Williams J.S. et al. Relationship between aldosterone and progesterone in the human menstrual cycle. J. Clin. Endocrinol. Metab. (2006) 91 3981-3987.
61. Arias-Loza P.A., Hu K., Dienesch C. et al. Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension (2007) 50 432-438.
62. Barbato J.C. Estrogen receptor activation - good, aldosterone receptor blockade - beneficial, communication between receptors...priceless. Hypertension (2007) 50 297-298.
63. Fagart J., Wurtz J.M., Souque A., Hellal-Levy C., Moras D., Rafestin-Oblin M.E. Antagonism in the human mineralocorticoid receptor. EMBO J. (1998) 17 3317-3325.
64. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol. Cell. Endocrinol. (2004) 217 255-261.
65. Nath A., Sitruk-Ware R. Different cardiovascular effects of progestins according to structure and activity. Climacteric (2009) 12(Suppl 1) 96-101.
66. Suzuki T., Nakamura Y., Moriya T., Sasano H. Effects of steroid hormones on vascular functions. Microsc. Res. Tech. (2003) 60 76-84.
67. White W.B., Hanes V., Chauhan V., Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension (2006) 48 246-253.
68. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341 709-717.
69. Pitt B., Remme W., Zannad F. et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348 1309-21.
70. Crackower M.A., Sarao R., Oudit G.Y. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 417 822-828.
71. Keidar S., Kaplan M., Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc. Res. (2007) 73 463-469.
72. Santos R.A., Ferreira A.J., Simões e Silva A.C. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp. Physiol. (2008) 93 519-527.
73. Ji H., Menini S., Zheng W., Pesce C., Wu X., Sandberg K. Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Exp. Physiol. (2008) 93 648-657.
74. Shenoy V., Grobe J.L., Qi Y. et al. 17beta-estradiol modulates local cardiac renin-angiotensin system to prevent cardiac remodeling in the DOCA-salt model of hypertension in rats. Peptides (2009) 30 2309-2315.
75. Eatman D., Wang M., Socci R.R., Thierry-Palmer M., Emmett N., Bayorh M.A. Gender differences in the attenuation of salt-induced hypertension by angiotensin (1-7). Peptides (2001) 22 927-933.
76. Neves L.A., Averill D.B., Ferrario C.M., Aschner J.L., Brosnihan K.B. Vascular responses to Angiotensin-(1-7) during the estrous cycle. Endocrine (2004) 24 161-165.
77. Grobe J.L., Katovich M.J. Alterations in aortic vascular reactivity to angiotensin 1-7 in 17-beta-estradiol-treated female SD rats. Regul. Pept. (2006) 133 62-67.
78. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., Adam A. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. (2005) 99 6-38.
79. Leeb-Lundberg L.M., Marceau F., Müller-Esterl W., Pettibone D.J., Zuraw B.L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. (2005) 57 27-77.
80. Sumino H., Ichikawa S., Kumakura H. et al. Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women. Hypertens. Res. (2003) 26 369-376.
81. Ichikawa A., Sumino H., Ogawa T., Ichikawa S., Nitta K. Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin- aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women. Geriatr. Gerontol. Int. (2008) 8 259-264.
82. Giménez J., García M.P., Serna M. et al. 17Beta-oestradiol enhances the acute hypotensive effect of captopril in female ovariectomized spontaneously hypertensive rats. Exp. Physiol. (2006) 91 715-722.
83. Vongpatanasin W., Tuncel M., Mansour Y., Arbique D., Victor R.G. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation (2001) 103 2903-2908.
84. Liu C.C., Kuo T.B., Yang C.C. Effects of estrogen on gender-related autonomic differences in humans. Am. J. Physiol. Heart Circ. Physiol. (2003) 285 H2188-H2193.
85. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N. Engl. J. Med. (1998) 339 321-328.
86. Maffei S., Del Ry S., Prontera C., Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin. Sci. (Lond). (2001) 101 447-453.
87. Kawano H., Nagayoshi Y., Soejima H. et al. B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram. Menopause (2008) 15 352-356.
88. Jankowski M., Rachelska G., Donghao W., McCann S.M., Gutkowska J. Estrogen receptors activate atrial natriuretic peptide in the rat heart. Proc. Natl. Acad. Sci. U S A (2001) 98 11765-11770.
89. Deng Y., Kaufman S. The influence of reproductive hormones on ANF release by rat atria. Life Sci. (1993) 53 689-696.
90. Babiker F.A., De Windt L.J., Van Eickels M. et al. 17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation (2004) 109 269-276.
91. Chapman A.B., Zamudio S., Woodmansee W. et al. Systemic and renal hemodynamic changes in the luteal phase of the menstrual cycle mimic early pregnancy. Am. J. Physiol. (1997) 273 F777-F782.
92. Chidambaram M., Duncan J.A., Lai V.S. et al. Variation in the renin angiotensin system throughout the normal menstrual cycle. J. Am. Soc. Nephrol. (2002) 13 446-452.
93. Okuniewski R., Davis E.A., Jarrott B., Widdop R.E. A comparison of the development of renal hypertension in male and female rats. Clin. Sci. (Lond). (1998) 95 445-451.
94. Falconnet C., Bochud M., Bovet P., Maillard M., Burnier M. Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent. J. Hypertens. (2004) 22 1213-1220.
95. Wing L.M., Reid C.M., Ryan P. et al; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting - enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. (2003) 348 583-592.
96. Reckelhoff J.F., Zhang H., Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension (2000) 35 480-483.
97. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA (1996) 275 1507-1513.
98. Garavaglia G.E., Messerli F.H., Schmieder R.E., Nunez B.D., Oren S. Sex differences in cardiac adaptation to essential hypertension. Eur. Heart J. (1989) 10 1110-1114.
99. Modena M.G., Muia N. Jr, Aveta P., Molinari R., Rossi R. Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension (1999) 34 1041-1046.
100. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA (1995) 273 1450-1456.
101. Hudson M., Rahme E., Behlouli H., Sheppard R., Pilote L. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - a population study. Eur. J. Heart Fail. (2007) 9 602-609.
102. Hoshi-Fukushima R., Nakamoto H., Imai H. et al. Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure. Am. J. Nephrol. (2008) 28 413-423.
103. Chappell M.C., Yamaleyeva L.M., Westwood B.M. Estrogen and salt sensitivity in the female mRen(2).Lewis rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2006) 291 R1557-R1563.
104. Yamaleyeva L.M., Pendergrass K.D., Pirro N.T., Gallagher P.E., Groban L., Chappell M.C. Ovariectomy is protective against renal injury in the high-salt-fed older mRen2.Lewis rat. Am. J. Physiol. Heart Circ. Physiol. (2007) 293 H2064-H2071.
105. Oestreicher E.M., Guo C., Seely E.W. et al. Estradiol increases proteinuria and angiotensin II type 1 receptor in kidneys of rats receiving L-NAME and angiotensin II. Kidney Int. (2006) 70 1759-1768.
106. Nakamura S., Yoshimura M., Nakayama M. et al. Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation (2004) 110 1787-1793.
107. Labrie F., Luu-The V., Bélanger A. et al. Is dehydroepiandrosterone a hormone? J. Endocrinol. (2005) 187 169-196.
108. Miyagawa K., Rösch J., Stanczyk F., Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat. Med. (1997) 3 324-327.
109. Hulley S., Grady D., Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA (1998) 280 605-613.
110. Rossouw J.E., Anderson G.L., Prentice R.L. et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 288 321-333.